Fedex Corporation Earnings

Fedex Corporation’s revenue fell -0.89% since last year same period to $21967Mn in the Q4 2024. On a quarterly growth basis, Fedex Corporation has generated 1.8% jump in its revenue since last 3-months.

Fedex Corporation’s net profit fell -17.67% since last year same period to $741Mn in the Q4 2024. On a quarterly growth basis, Fedex Corporation has generated -6.68% fall in its net profits since last 3-months.

Fedex Corporation’s net profit margin fell -16.92% since last year same period to 3.37% in the Q4 2024. On a quarterly growth basis, Fedex Corporation has generated -8.32% fall in its net profit margins since last 3-months.

Fedex Corporation’s price-to-earnings ratio after this Q4 2024 earnings stands at 17.61.

Fedex Corporation’s earning per share (EPS) estimates for the current quarter stand at 3.95 - a -17.02% fall from last quarter’s estimates.

Fedex Corporation’s earning per share (EPS) estimates for the current year stand at 3.95.

Fedex Corporation’s earning per share (EPS) jumped 1.5% since last year same period to 4.05 in the Q4 2024. This indicates that the Fedex Corporation has generated 1.5% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Fedex Corporation’s return on assets (ROA) stands at 0.05.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Fedex Corporation’s return on equity (ROE) stands at 0.15.

Fedex Corporation declared 1.38 dividend per share during the earnings announcement for Q4 2024.